

Identification of human cathelicidin peptide LL-37 as a ligand for macrophage integrin $\alpha_M\beta_2$ (Mac-1, CD11b/CD18) that promotes phagocytosis by opsonizing bacteria

Valeryi K Lishko
Benjamin Moreno
Nataly P Podolnikova
Tatiana P Ugarova

Center for Metabolic and Vascular
Biology, School of Life Sciences,
Arizona State University, Tempe,
AZ, USA

Abstract: LL-37, a cationic antimicrobial peptide, has numerous immune-modulating effects. However, the identity of a receptor that mediates the responses in immune cells remains uncertain. We have recently demonstrated that LL-37 interacts with the α_M I-domain of integrin $\alpha_M\beta_2$ (Mac-1), a major receptor on the surface of myeloid cells, and induces a migratory response in Mac-1-expressing monocyte/macrophages as well as activation of Mac-1 on neutrophils. Here, we show that LL-37 and its C-terminal derivative supported strong adhesion of various Mac-1-expressing cells, including human embryonic kidney cells stably transfected with Mac-1, human U937 monocytic cells, and murine IC-21 macrophages. The cell adhesion to LL-37 was partially inhibited by specific Mac-1 antagonists, including monoclonal antibody against the α_M integrin subunit and neutrophil inhibitory factor, and completely blocked when anti-Mac-1 antibodies were combined with heparin, suggesting that cell surface heparan sulfate proteoglycans act cooperatively with integrin Mac-1. Coating both gram-negative and gram-positive bacteria with LL-37 significantly potentiated their phagocytosis by macrophages, and this process was blocked by a combination of anti-Mac-1 monoclonal antibody and heparin. Furthermore, phagocytosis by wild-type murine peritoneal macrophages of LL-37-coated latex beads, a model of foreign surfaces, was several fold higher than that of untreated beads. In contrast, LL-37 failed to augment phagocytosis of beads by Mac-1-deficient macrophages. These results identify LL-37 as a novel ligand for integrin Mac-1 and demonstrate that the interaction between Mac-1 on macrophages and bacteria-bound LL-37 promotes phagocytosis.

Keywords: LL-37, integrin $\alpha_M\beta_2$, Mac-1, CD11b/CD18, phagocytosis, opsonin

Introduction

LL-37, a member of the cathelicidin family of mammalian host defense peptides and the only representative of this group in humans, exerts numerous immune-modulating effects in response to infections and other changes in the status of immune system.¹ LL-37 is derived by a proteolytic cleavage in the C-terminal part of its precursor cationic antimicrobial protein-18 (hCAP-18) when this protein is secreted from cells during the immune-inflammatory response.² While initially isolated from neutrophils, hCAP-18/LL-37 has been subsequently found in other blood cells including monocyte/macrophages, eosinophils, natural killer cells, T-cells, and B-cells in addition to mast cells and various epithelial cells.³ The biological significance of LL-37 in innate host defense has been established in the studies of its mouse homologue cathelicidin-related AMP (CRAMP), which shares with LL-37

Correspondence: Tatiana P Ugarova
Center for Metabolic and Vascular
Biology, School of Life Sciences, MC
4501, Arizona State University, Tempe,
AZ 85287, USA
Email Tatiana.Ugarova@asu.edu

similar gene structure and tissue distribution: mice null for the CRAMP gene are more susceptible to streptococcal infections.⁴ Furthermore, systemic expression of the hCAP-18/LL-37 gene or LL-37 injection protects rodents from septic death.⁴⁻⁶

Similar to other antimicrobial cationic peptides, LL-37 mainly consists of positively charged and hydrophobic residues and has a propensity to fold into the amphipathic α -helix in physiologically relevant buffers and environments mimicking biological membranes. The cationic and amphipathic nature of antimicrobial peptides is generally associated with their bactericidal activity: the overall positive charge endows them with the ability to bind to the negatively charged bacterial wall and the anionic cell membrane.^{7,8} After insertion into the membrane, antimicrobial peptides are thought to disrupt the integrity of the bilayer resulting in killing of bacteria. Although the direct bactericidal activity of LL-37 has been documented in vitro under low salt conditions and in the absence of divalent cations such as Ca^{2+} and Mg^{2+} , it is significantly reduced when assayed in physiologically relevant media and at the peptide concentrations that are found at the sites of infection or inflammation.⁶ These observations led to an idea that the membrane-targeting activity of LL-37 may not be the primary function of this peptide.^{6,9}

Numerous studies have demonstrated that LL-37 exerts a multitude of effects on the immune cells in vitro.^{10,11} LL-37 has a chemotactic effect, acting upon and inducing migration of human peripheral blood monocytes, neutrophils, and T-cells.¹² It was shown to modulate the expression of hundreds of genes in monocytes and other cells, including those for chemokines and chemokine receptors.¹³ Human neutrophils exposed to LL-37 increase the production of reactive oxygen species¹⁴ and exhibit delayed apoptosis.¹⁵ Thus, during infection, LL-37 released by degranulation of neutrophils or secreted from other cells would be expected to modulate the innate immune response through a variety of ways. However, the mechanisms underlying these LL-37 responses have not been well characterized, and to date, several receptors were reported to associate with LL-37-induced immunomodulation.^{12,16-19}

We have recently characterized the recognition specificity of integrin $\alpha_M\beta_2$ (Mac-1, CD11b/CD18), a receptor with broad ligand-binding specificity expressed on neutrophils and monocyte/macrophages, and identified structural motifs present in many Mac-1 ligands.²⁰ In particular, the α_M I-domain, a ligand-binding region of Mac-1, has affinity for short 6–9 mer amino acid sequences containing a core of basic residues flanked by hydrophobic residues in which negatively charged residues are strongly disfavored. The binding motifs for Mac-1 can be coded as HyBH_y, HyHyBH_y, HyBH_yHy, and HyHyBH_yHy, where Hy represents any hydrophobic

residue and B is either arginine or lysine. Other amino acids can also be found, but in general, their proportion within the Mac-1-binding motifs is very small. Inspection of the LL-37 sequence revealed that it contains several putative Mac-1 recognition sites and may represent a ligand for Mac-1. Indeed, we have shown that recombinant α_M I-domain bound several overlapping LL-37-derived peptides and the full-length LL-37 peptide that induced Mac-1-dependent migration of monocyte and macrophages as well as neutrophil activation.²⁰

In this study, we have further examined the interaction of LL-37 with Mac-1-expressing cells. These studies were initiated to test the hypothesis that cationic LL-37, when deposited on the anionic bacterial surface, would serve as an adhesive ligand for Mac-1 on macrophages and promote phagocytosis. The results demonstrate that LL-37 is a potent opsonin that augments phagocytosis of both Gram-negative and Gram-positive strains through a cooperative binding of integrin Mac-1 and heparan sulfate proteoglycans (HSPGs) on the surface of macrophages.

Materials and methods

Peptides, proteins, and monoclonal antibodies

The LL-37 peptide (¹LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLPRTES³⁷), its C-terminal part (residues 18–37; termed K18-37), and LL-37-GY containing two additional C-terminal residues Gly-Tyr were obtained from AnaSpec, Inc. (San Jose, CA, USA) and Peptide 2.0 (Chantilly, VA, USA). Alternatively, recombinant LL-37 was prepared as described.²¹ Briefly, LL-37 was expressed as a fusion protein with glutathione *S*-transferase. The cDNA of LL-37 (from True Clone, Rockville, MD, USA) was cloned in the pGEX-4T-1 expression vector (GE Healthcare, Chicago, IL, USA). Recombinant GST-LL-37 was purified from a soluble fraction of *Escherichia coli* lysates by affinity chromatography using glutathione agarose. LL-37 was separated from GST by digestion with thrombin followed by gel filtration on Sephadex G-25. The isolated peptide was analyzed by Western blotting using polyclonal antibody sc-50423 (Santa Cruz Biotechnology Inc., Dallas, TX, USA). LL-37-GY was labeled with iodine-125 using IODO-GEN (Thermo Fisher Scientific, Waltham, MA, USA) to the specific activity of 6×10^9 cpm/ μmol . Fibrinogen, depleted of fibronectin and plasminogen, was obtained from Enzyme Research Laboratories (South Bend, IN, USA). Recombinant α_M I-domain (residues Glu¹²³-Lys²¹⁸) was prepared as described earlier.²² The monoclonal antibodies (mAbs) 44a, directed against the human α_M integrin subunit, mAb IB4, against the human β_2 integrin subunit, and mAb M1/70, against the mouse α_M subunit, were purified

from the conditioned media of hybridoma cells obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) using protein A agarose. Mouse (G3A1) mAb IgG1 isotype control for mAb 44a was from Cell Signaling (Danvers, MA, USA) and rat IgG2b (MCA1125) isotype control for mAb M1/70 was from Bio-Rad Laboratories Inc. (Hercules, CA, USA). The anti- β_1 mAb AIIB2 was from Developmental Studies Hybridoma Bank (Iowa City, IA, USA). Bovine serum albumin (BSA), polyvinylpyrrolidone, heparin (sodium salt; from porcine intestinal mucosa), and poly-L-lysine (molecular weight 90,000 Da) were obtained from Sigma-Aldrich Co. (St Louis, MO, USA). MC 4501, and fluorescent latex beads (FluoroSpheres, 1 μ m) were from Thermo Fisher Scientific.

Synthesis of cellulose-bound peptide libraries

The FALL-39-derived peptide library assembled on a single cellulose membrane support was prepared by parallel spot synthesis as described earlier.^{23,24} The membrane-bound peptides were tested for their ability to bind the α_M I-domain according to a procedure described earlier.²³ In brief, the membrane was blocked with 1% BSA and then incubated with 10 μ g/mL of ¹²⁵I-labeled α_M I-domain in Tris-buffered saline containing 1 mM MgCl₂. After washing, the membrane was dried, and the α_M I-domain binding was visualized by autoradiography.

Cells

Human embryonic kidney cells (HEK293) and HEK293 cells stably expressing integrin Mac-1 were described earlier.^{25,26} The cells were maintained in Dulbecco's Modified Eagle's Medium (Mediatech Inc., Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS) and antibiotics. U937 human monocytic cells were grown in Roswell Park Memorial Institute (RPMI) containing 10% FBS and antibiotics. The THP-1 human monocytic cell line was purchased from ATCC and cultured in RPMI containing 10% FBS, antibiotics, and 0.05 mM 2-mercaptoethanol. The THP-1 cells were differentiated into macrophages by adding 10 ng/mL of phorbol 12-myristate 13-acetate (PMA) into the medium for 48 hours as described earlier.²⁷ The IC-21 murine macrophage cell, *Staphylococcus aureus* subsp. aureus 25923 (ATCC 25923) and *E. coli* MG-1655 (ATCC 700926) were from ATCC. Resident peritoneal leukocytes were obtained from 8-week-old wild-type C57BL/6 and Mac-1^{-/-} mice (The Jackson Laboratories, Bar Harbor, ME, USA) by lavage using cold phosphate-buffered saline (PBS) containing

5 mM EDTA. The population of wild-type leukocytes contained 46.3% \pm 2.7% and 44.1% \pm 3.6% of macrophage and lymphocytes, respectively, and that obtained from Mac-1^{-/-} mice consisted of 37.3% macrophages and 53% \pm 2.9% lymphocytes. Macrophages were obtained by plating a total population of peritoneal leukocytes on glass cover slides for 2 hours at 37°C in 5% CO₂ followed by the removal of nonadherent cells (mainly lymphocytes) that resulted in the enrichment of adherent macrophages.

Cell adhesion assays

Adhesion assays were performed essentially as described earlier.^{25,26} Briefly, the wells of 96-well microtiter plates (Immulon 4HBX; Thermo Labsystems, Franklin, MA, USA) were coated with various concentrations of LL-37- or LL-37-derived peptides for 3 hours at 37°C and postcoated with 1.0% PVP for 1 hour at 37°C. Fibrinogen was coated at 2.5 μ g/mL. Cells were labeled with 5 μ M calcein for 30 minutes at 37°C and washed twice with Hanks' balanced salt solution containing 0.1% BSA. Aliquots (100 μ L) of labeled cells (5 \times 10⁵/mL) were added to each well and allowed to adhere for 30 minutes at 37°C. The nonadherent cells were removed by two washes with PBS. Fluorescence was measured in a CytoFluorII fluorescence plate reader (Thermo Fisher Scientific). In inhibition experiments, cells were mixed with different concentrations of mAbs, neutrophil inhibitory factor (NIF), heparin, or the K18-37 peptide for 15 minutes at 22°C before they were added to the wells coated with adhesive substrates.

Phagocytosis assays

A suspension of fluorescein-labeled *S. aureus* particles (4 \times 10⁷/mL) (pHrodo® Green; Thermo Fisher Scientific) was incubated with different concentrations of LL-37 or K18-37 for 20 minutes at 22°C, and then unbound peptide was removed by centrifugation. IC-21 murine macrophages (10⁶/mL) were mixed with peptide-coated *S. aureus* particles. After incubating for 60 minutes at 37°C, nonphagocytosed of *S. aureus* particles were separated from macrophages by filtering the suspension using Transwell inserts with a pore size of 3.0 μ m (Costar; Corning Incorporated, Corning, NY, USA). Macrophages were transferred to the wells of 96-well microtiter plates, and trypan blue (0.2%) was applied to wells to quench the fluorescence of any remaining *S. aureus* outside of macrophages. The ratio of bacterial particles per macrophage was quantified taking photographs of three fields for each well using a Leica DM4000 B microscope (Leica Microsystems, Wetzlar, Germany) with a 20 \times objective.

Phagocytosis by adherent macrophages was performed using fluorescein isothiocyanate (FITC)-labeled bacteria. To label *E. coli*, bacteria were grown overnight and diluted with 50 mM NaHCO₃, pH 8.5 to OD=1.5. FITC was dissolved in dimethyl sulfoxide and added to 0.5 mL *E. coli* suspensions to a final concentration of 0.1 µg/mL. Suspensions were incubated for 1 hour at 22°C. Labeled bacteria were washed four times with 4×1 mL PBS by centrifugation at 1,800×g for 5 minutes. FITC-labeled *E. coli* (100 µL, 3×10⁸ particles/µL) were incubated with LL-37 for 30 minutes at 37°C and washed with RPMI by centrifugation at 1,800×g for 5 minutes to remove unbound peptide. The pellet was resuspended in RPMI +10% FBS at the concentration of 10⁷ bacterial particles/mL. For control experiments, media were substituted for LL-37, but all other aspects of the procedure were the same. For selected experiments, fluorescent 1.0 mM latex beads were incubated with LL-37, washed, and applied at 2.5×10⁶ to wells containing macrophages. IC-21 murine macrophages, macrophages isolated from the mouse peritoneum, and differentiated THP-1 human macrophages were resuspended in RPMI +10% FBS and cultured in Costar 48-well plates (2.5×10⁵/well) for 3–5 hours at 37°C. After the media were aspirated, adherent cells were washed and incubated with 0.5 mL FITC-labeled *E. coli* suspensions, *S. aureus* particles, or fluorescent latex beads for 1 hour at 37°C. Cells were washed three times with 3×1 mL PBS, and phagocytosed bacteria or beads were counted in the presence of trypan blue.

In comparative studies of LL-37-induced phagocytosis by macrophages isolated from the peritoneum of wild-type and Mac-1^{-/-} mice, the cells were allowed to adhere to glass cover slides for 2 hours at 37°C. After removing nonadherent cells, fluorescent latex beads treated with LL-37 were added to the cells and incubated for 30 minutes at 37°C. Cells were washed with PBS, fixed with 2% paraformaldehyde, and beads counted. Animal studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee of the Arizona State University (protocol number 13-1271R) and Mayo Clinic in Arizona (protocol number A22313).

Statistical analysis

All data are presented as the mean ± standard error. The statistical differences between two groups were determined using a Student's *t*-test from SigmaPlot 11.0 software (Systat Software, San Jose, CA, USA). For multiple comparisons,

the Bonferroni correction method was used. Differences were considered significant at $P < 0.05$.

Results

Analyses of the α_M I-domain-binding capacity of the FALL-39-derived peptides

We previously screened a small peptide library consisting of eleven 9-mer peptides spanning the sequence of LL-37 for binding of recombinant α_M I-domain.²⁰ A remarkable feature of LL-37 is that ten overlapping peptides that bound the α_M I-domain formed a continuous stretch. To validate these data, we synthesized an additional library spanning the sequence of FALL-39, an active derivative of LL-37, which includes the sequence of LL-37 and two additional N-terminal residues Phe and Ala present in the hCAP-18 cathelin precursor (Figure 1A).²⁸ Similar to the




Figure 1 Characterization of the α_M I-domain recognition motifs in the FALL-39 sequence.

Notes: (A) The amino acid sequence of FALL-39 and the 3D structure of LL-37 based on PDB Id: 2K6O. Positively charged (blue) and hydrophobic (tan) residues in the C-terminal part of the peptide are numbered. The underlined sequences denote the α_M I-domain recognition patterns. (B) The peptide library derived from the FALL-39 sequence (left panel) consisting of 9-mer peptides with a three-residue offset was incubated with ¹²⁵I-labeled α_M I-domain, and the α_M I-domain binding was visualized by autoradiography. Control – a spot containing only the β -Ala spacer used for the attachment of peptides to the cellulose membrane. The α_M I-domain binding observed as dark spots was analyzed by densitometry (middle column). The numbers show the relative binding of the α_M I-domain to peptides expressed as a percentage of the intensity of spot 3. The peptide energies (right column) that serve as a measure of probability each peptide can interact with the α_M I-domain were calculated as described.²⁰

LL-37 library, all overlapping peptides in the FALL-39 scan bound the α_M I-domain. Densitometric analyses of the library indicated that the most active peptides were present in spots 3 and 6 (Figure 1B). The α_M I-domain-binding peptides were analyzed by a previously developed algorithm, which determines the capacity of each peptide to interact with the α_M I-domain.²⁰ The program assigns each peptide the energy value that serves as a measure of probability that the α_M I-domain binds this sequence: the lower the energy, the higher the likelihood that the sequence binds the α_M I-domain. As determined from the analyses of numerous Mac-1 ligands, the peptides that strongly bind α_M I-domain have energy values in the range of -20 kJ/mol to 2 kJ/mol.²⁰ Based on the application of the algorithm, all peptides in the FALL-39 library had energies between -15.5 kJ/mol and -0.9 kJ/mol (Figure 1B). Moreover, the two most active peptides in spots 3 and 6 had the lowest energies. The finding that overlapping peptides in the library form a continuous stretch containing strong α_M I-domain recognition cores ⁵FFRKSK¹⁰, ¹²KIGK¹⁵, ¹⁷FKRIVQRIK²⁵, and ²⁷FLRNLVPR³⁴ in which basic residues are surrounded or flanked by hydrophobic residues suggests that FALL-39 and LL-37 have the strong α_M I-domain-binding potential.

LL-37 supports adhesion of the Mac-1-expressing HEK293 cells

The interaction of the α_M I-domain with LL-37-derived peptides suggests that LL-37 may support adhesion of Mac-1-expressing cells. To investigate this possibility, we performed adhesion with immobilized LL-37 using various Mac-1-expressing cells. As shown in Figure 2A, LL-37 supported efficient adhesion of a model HEK293 cell line genetically engineered to stably express integrin Mac-1 (Mac-1-HEK293 cells). Cell attachment was dose dependent with saturable adhesion occurring at a coating concentration of 2 μ g/mL. At this concentration, $52\% \pm 5\%$ of added cells adhered to LL-37 ($n=6$). Using ¹²⁵I-labeled LL-37-GY, we verified that peptide was immobilized on plastic in a concentration-dependent manner and supported adhesion (Figure S1). By contrast, no adhesion of wild-type HEK293 cells in the range of 0 – 1.0 μ g/mL coating concentrations of LL-37 was observed (Figure 2A). At higher coating concentrations (1 – 4 μ g/mL), LL-37 supported adhesion of wild-type HEK293 cells; however, maximal adhesion did not reach the level attained with Mac-1-HEK293 cells (Figure 2A). Human monocytic U937 cells naturally expressing Mac-1 also adhered to LL-37 in a concentration-dependent manner (data not shown). The role of Mac-1 in the interaction

of Mac-1-HEK293 cells with LL-37 was determined using function-blocking mAb 44a directed to the human α_M integrin subunit. mAb 44a inhibited adhesion of the Mac-1-HEK293 cells by $\sim 90\%$ at the low (0.4 μ g/mL) coating concentrations of LL-37 (Figure 2B, middle panel). An isotype control IgG1 for mAb 44a was not active. At higher coating concentrations of LL-37, mAb 44a was less effective: at 0.5 μ g/mL of LL-37, it inhibited adhesion by $\sim 20\%$ (data not shown), and at 2 μ g/mL, it produced only $\sim 5\%$ inhibition (Figure 2B, right panel). The role of Mac-1 in mediating adhesion to LL-37 was also examined using NIF, a specific inhibitor of the α_M I-domain–ligand interactions.²⁹ As seen with mAb 44a, NIF effectively blocked adhesion of the Mac-1-HEK293 cells to the low (0.4 μ g/mL), but not high (≥ 2 μ g/mL) concentrations of LL-37 (Figure 2B). Partial inhibition of cell adhesion by specific anti-Mac-1 reagents and the fact that wild-type HEK293 cells were capable of mediating adhesion to LL-37 suggest that other receptors and/or cell structures contribute to cell attachment to LL-37.

It is well known that several integrins, including Mac-1, cooperate with cell surface HSPGs during cell adhesion to the extracellular matrix proteins.^{30,31} LL-37 is a highly positively charged molecule and is expected to bind negatively charged HSPGs. To investigate whether HSPGs on wild-type and Mac-1-HEK293 cells are required for cell adhesion to LL-37, we examined the effect of heparin. Heparin at 20 μ g/mL was a strong inhibitor of adhesion of wild-type HEK293 cells at all coating concentrations of LL-37 (Figure 2B). We also considered that β_1 integrins, the major type of integrins on the surface of these cells,²⁶ may contribute to LL-37 recognition. However, we found no significant effect of anti- β_1 mAb alone or in combination with heparin, suggesting that on the surface of wild-type HEK293 cells, HSPGs are mainly involved in LL-37 binding (Figure 2B). With the Mac-1-HEK293 cells, heparin effectively inhibited cell adhesion to wells coated with the low concentration of LL-37 (0.4 μ g/mL), and both anti- α_M mAb 44a and heparin completely blocked adhesion (Figure 2B). However, heparin was much less effective in blocking cell adhesion to the high (2 μ g/mL) coating concentration of LL-37 (Figure 2B). Nevertheless, when cells were treated with both mAb 44a and heparin, cell adhesion was inhibited by $>95\%$.

Consistent with the role of Mac-1 in adhesion to LL-37, Mac-1-HEK293 cells spread in a concentration-dependent manner with the formation of stress fibers, as detected by staining for actin with Alexa Fluor 546-conjugated phalloidin (Figure 2C, upper panel). By contrast, wild-type HEK293 cells remained round when plated on slides coated with the




Figure 2 LL-37 supports adhesion of the $\alpha_v\beta_3$ -expressing cells.

Notes: (A) Aliquots (100 μ L; 5×10^4 /mL) of Mac-1-expressing HEK293 (Mac-1-HEK293) and wild-type HEK293 (HEK293) cells labeled with calcein were added to microtiter wells coated with different concentrations of LL-37 and postcoated with 1% PVP. After 30 minutes at 37°C, nonadherent cells were removed by washing and fluorescence of adherent cells was measured in a fluorescence reader. A representative of six experiments in which two cell lines were tested side by side is shown. Data presented are means for triplicate determinations, and error bars represent SE. Fluorescence is expressed in arbitrary units (a.u.). (B) Wild-type HEK293 cells were preincubated with anti- β_1 mAb (10 μ g/mL), heparin (20 μ g/mL) or their mixture for 15 minutes at 22°C and added to wells coated with 2 μ g/mL LL-37. Mac-1-HEK293 cells were preincubated with anti- α_M mAb 44a (10 μ g/mL), heparin (20 μ g/mL) or their mixture and added to wells coated with 0.4 μ g/mL or 2 μ g/mL LL-37. Adhesion in the absence of Mac-1 inhibitors and heparin was assigned a value of 100%. Data shown are mean \pm SE from three to four separate experiments with triplicate measurements. * $P \leq 0.05$ and ** $P \leq 0.01$ compared with control adhesion in the absence of inhibitors. (C) Mac-1-HEK293 (upper panel) and HEK293 cells (bottom panel) were plated on glass slides and allowed to adhere for 30 minutes at 37°C. Nonadherent cells were removed and adherent cells were fixed with 2% paraformaldehyde followed by staining with Alexa Fluor 546 phalloidin. The cells were imaged with a Leica SP5 laser scanning confocal microscope with a 63 \times objective.

Abbreviations: PVPV, polyvinylpyrrolidone; SE, standard error.

low concentrations of LL-37 (0.2–1.0 μ g/mL) and spread at higher LL-37 concentrations (2 μ g/mL). However, their morphology was entirely different from that of Mac-1-HEK293 cells with many actin-based filopodia/microspikes formed at the cell periphery (Figure 2C, bottom panel). Together, these results identify LL-37 as an adhesive ligand for Mac-1 and indicate that on the surface of Mac-1-HEK293 cells, Mac-1 and HSPGs are involved in LL-37 recognition. They further suggest that the engagement of LL-37 by Mac-1 during adhesion transduces intracellular signaling, leading to assembly of the actin cytoskeleton.

The C-terminal LL-derived peptide K18-37 supports and inhibits adhesion of Mac-1-expressing HEK293 cells

To investigate whether the C-terminal part of LL-37, 18 KRIVQRIKDFLRNLPRTES 37 , previously reported to be mainly responsible for the antimicrobial effect of LL-37, 2,32 was involved in supporting adhesion, we examined dose dependency of adhesion of Mac-1-HEK293 cells to the K18-37 peptide. As shown in Figure 3A, K18-37 supported efficient cell adhesion. Adhesion was concentration dependent,




Figure 3 Adhesion of Mac-1-HEK293 and wild-type HEK293 cells to the LL-37-derived peptide K18-37.

Notes: (A) Aliquots (100 μL ; $5 \times 10^6/\text{mL}$) of Mac-1-HEK293 cells were labeled with calcein and added to microtiter wells coated with different concentrations of K18-37. After 30 minutes at 37°C , nonadherent cells were removed and adhesion was measured. Adhesion was expressed as percent of added cells. The data shown are mean and SE from four experiments with triplicate determinations at each point. (B) Calcein-labeled Mac-1-HEK293 cells were incubated with different concentrations of K18-37 (\bullet) or control peptide (\blacktriangledown) for 15 minutes at 22°C and added to wells coated with 2.5 $\mu\text{g/mL}$ fibrinogen and postcoated with 1% PVP. Adhesion (left ordinate) was determined after 30 min. Right ordinate, Mac-1-HEK293 cells were treated with different concentrations of K18-37 for 15 minutes at 22°C . Cells were centrifuged and fluorescence of cell supernatants determined (\circ). The data shown are the mean \pm SE from two experiments each with triplicate determinations.

Abbreviations: SE, standard error; PVP, polyvinylpyrrolidone.

and at 5 $\mu\text{g/mL}$, $47\% \pm 7\%$ of added cells adhered to peptide (maximal adhesion). We next evaluated the effect of soluble K18-37 on adhesion of Mac-1-HEK cells to immobilized fibrinogen, a well-established Mac-1 ligand. It has been reported that α_M I-domain-binding peptides derived from different ligands inhibit Mac-1-mediated adhesion to the fibrinogen-derived D fragment,²⁰ which contains the $\gamma^{383}\text{MKI-IPFNRLTIG}^{395}$ sequence, the prototype adhesive sequence for the α_M I-domain.^{33,34} As shown in Figure 3B, preincubation of cells with soluble K18-37 dose dependently inhibited cell adhesion with an half maximal inhibitory concentration (IC_{50}) of 6 $\mu\text{g/mL}$, indicating mutual exclusive binding of K18-37 to the α_M I-domain. Control peptide DIDPKLKWD (11.1 kJ/mol) was inactive. Previous studies demonstrated that soluble LL-37 affects the membrane integrity of leukocytes, albeit at the high concentrations ($>50 \mu\text{g/mL}$).^{35,36} We reasoned that if soluble K18-37 also damaged the membrane, it would result in the leakage of calcein and decreased fluorescence of adherent cells, giving a false impression of reduced adhesion. Therefore, in control experiments, we examined the effect of K18-37 by determining the leakage of calcein loaded into the Mac-1-HEK cells. As shown in Figure 3B (left ordinate), peptide was not active even at 50 $\mu\text{g/mL}$. Thus, inhibition of cell adhesion by K18-37 is unlikely due to its effect on the cell membrane.

Adhesion of mouse macrophages to the K18-37 peptide is partly mediated by Mac-1 and HSPGs

The human LL-37 peptide has been shown to exert its immunomodulatory effects across a wide range of species,

including mouse, rat, rabbit, and human.^{13,37,38} Therefore, we examined the ability of LL-37 and K18-37 to support the adhesion of the murine macrophage cell line IC-21. Macrophages strongly adhered to LL-37 and K18-37 (Figure 4A, shown for K18-37). A similar pattern of inhibition by anti- α_M antibodies that has been observed with human Mac-1-HEK293 cells was detected with IC-21 macrophages, that is, while mAb M1/70 against the murine α_M integrin subunit was a strong inhibitor of adhesion at the low coating concentrations of peptide ($>90\%$ inhibition at 0–0.5 $\mu\text{g/mL}$), it gradually lost its blocking potency as the coating concentration increased (Figure 4A). At 2 $\mu\text{g/mL}$ of K18-37, mAb M1/70 inhibited adhesion by $46\% \pm 9\%$ (Figure 4B). An isotype control IgG2b for mAb M1/70 had no significant effect. Pretreatment of cells with heparin (20 $\mu\text{g/mL}$) resulted in only partial inhibition of adhesion at both low (0.5 $\mu\text{g/mL}$) and high (2 $\mu\text{g/mL}$) coating concentrations of K18-37 ($25\% \pm 13\%$ and $32\% \pm 12\%$; Figure 4B). Pretreatment of cells with both mAb M1/70 and heparin resulted in the complete inhibition of adhesion only at the low, but not high concentrations of K18-37 (Figure 4B). These results suggest that on the surface of IC-21 macrophages, Mac-1 and HSPGs are involved in adhesion to K18-37; however, other receptors and/or glycosaminoglycans may participate in peptide binding.

The interaction of LL-37 with bacteria enhances phagocytosis by macrophages via Mac-1 and HSPGs

Since LL-37 supported efficient cell adhesion, we questioned whether LL-37 deposited on the bacterial surface




Figure 4 Adhesion of murine IC-21 macrophages to the LL-37-derived peptide K18-37.

Notes: (A) Calcein-labeled IC-21 macrophages were preincubated for 15 minutes at 22°C with buffer (●) or 10 µg/mL mAb M1/70 (anti- α_M) (■). Aliquots (5×10⁶/0.1 mL) of cells were added to microtiter wells coated with different concentrations of K18-37 (0–2 µg/mL) and postcoated with 1% PVP. After 30 minutes at 37°C, nonadherent cells were removed by washing and adhesion was determined. (B) IC-21 macrophages were preincubated with anti- α_M mAb M1/70 (10 µg/mL), heparin (20 µg/mL) or their mixture and added to wells coated with 0.5 µg/mL and 2 µg/mL K18-37. Adhesion in the absence of inhibitors and heparin was assigned a value of 100%. The data shown are the mean ± SE from five to six experiments each with triplicate determinations. *P≤0.05 and **P≤0.01 compared with control adhesion in the absence of inhibitors.

Abbreviations: PVP, polyvinylpyrrolidone; SE, standard error.

can serve as an adhesive ligand for Mac-1 on macrophages, thereby promoting bacterial phagocytosis. We first assessed the binding capacities of representative gram-negative and gram-positive bacteria for LL-37 and compared them with several mammalian cells. As shown in Figure 5, U937, IC-21, and erythrocytes bound significantly less ¹²⁵I-labeled LL-37-GY than the tested bacteria. At 5 µg/mL of soluble peptide, the binding capacity of *E. coli* was 1.4±0.1 fg/µm² similar to that of the plastic used in adhesion experiments. While *Salmonella* bound 1.8-fold less LL-37 than *E. coli*, the quantity of bound peptide was still ~17-fold higher than that associated with mammalian cells. The differential binding capacity of LL-37 is in agreement with the previously discussed characteristics that distinguish bacterial and mammalian cell membranes.^{8,39} These results suggest that the high density of LL-37 bound to the bacterial surface may support macrophage attachment.

To assess whether LL-37 influences phagocytosis of bacteria by macrophages, suspensions of fluorescein-labeled *S. aureus* particles and *E. coli* were incubated with LL-37. After the removal of nonbound peptide, the coated bacteria were incubated with IC-21 macrophages for 60 minutes at 37°C with the subsequent removal of nonphagocytosed particles. Before photographing the phagocytosed cells, trypan blue was added to quench the fluorescence of the remaining extracellular-bound bacterial particles. As shown in Figure 6A and B, treatment of *S. aureus* with 5 µg/mL of LL-37 significantly augmented phagocytosis by macrophages. The C-terminal K18-37 peptide was also active in enhancing phagocytosis of *S. aureus* particles (Figure 6A). Moreover, the effect of




Figure 5 Binding density of LL-37 on the surface of mammalian and microbial cells.

Notes: Cell suspensions were incubated with 5 µg/mL ¹²⁵I-LL-37-GY for 20 minutes at 22°C. Nonbound peptide was removed by centrifugation at 200 g (mammalian cells) or 2,000 g (bacteria) for 10 minutes. The pellet was washed with PBS, resuspended in 100 µL PBS and radioactivity was measured. The data shown are the mean ± SE from three experiments each with duplicate measurements.

Abbreviations: PBS, phosphate-buffered saline; SE, standard error; *E. coli*, *Escherichia coli*.

LL-37 was dose dependent and saturable at 10 µg/mL (Figure 6C, shown for *E. coli*).

To investigate whether integrin Mac-1 and HSPGs on macrophages are involved in promoting phagocytosis of LL-37-coated bacteria, we examined the effects of anti- α_M mAb M1/70 and heparin. On its own, mAb M1/70 did not inhibit LL-37-mediated phagocytosis (Figure 6D). In addition, heparin only slightly decreased the number of phagocytosed




Figure 6 Effect of LL-37 on phagocytosis of *S. aureus* particles and *E. coli* by suspensions of murine IC-21 macrophages.

Notes: (A) Fluorescent *S. aureus* particles (4×10^7 /mL) were preincubated with LL-37 (5 μ g/mL), K18-37 (10 μ g/mL), or poly-L-lysine (10 μ g/mL) for 20 minutes at 22°C. Soluble peptide was removed by centrifugation. Peptide-coated particles were incubated with suspensions of IC-21 macrophages (10^6 /mL) for 60 minutes at 37°C, and nonphagocytosed particles were separated from cells by filtering the suspensions using 3 μ m pore transwell inserts. Macrophages were transferred to wells of 96-well plates, and trypan blue was added to the wells. The ratio of bacterial particles per macrophage was quantified for five random fields per well using a 20 \times objective. Data are mean \pm SE per cell from five or more experiments. ** $P \leq 0.01$ compared with untreated control *S. aureus*. (B) Bright field (a and e), fluorescence (b and f), and merged (c and g) images of IC-21 macrophages incubated with LL-37-coated (a–c) or uncoated (e–g) control bacteria. The representative low power (20 \times) fields are shown. Enlarged images (d and h) of macrophages shown in the boxed areas in c and g. Phagocytosed bacterial particles are labeled in green. (C) Concentration-dependent effect of LL-37 on phagocytosis of *E. coli* by macrophages. Fluorescently labeled *E. coli* cells were incubated with different concentrations of LL-37 for 20 minutes at 22°C. After the removal of nonbound peptide by centrifugation, LL-37-coated *E. coli* were incubated with IC-21 macrophages (10^6 /mL) for 60 minutes at 37°C. Data are expressed as mean \pm SE of ratios of bacteria per macrophage. A representative of three experiments is shown. (D) Fluorescent *S. aureus* particles were preincubated with LL-37 (5 μ g/mL) for 20 minutes at 22°C. Soluble peptide was removed by centrifugation. Peptide-coated bacterial particles were incubated with IC-21 macrophages (10^6 /mL) in the presence of anti- α_M mAb M1/70 (20 μ g/mL), heparin (20 μ g/mL), or their mixture. After 60 minutes incubation at 37°C, nonphagocytosed *S. aureus* particles were removed, and phagocytosis was determined. Data shown are mean \pm SE of bacterial particles per cell of five random fields determined for each condition and are representative of three separate experiments. * $P \leq 0.05$ and ** $P \leq 0.01$.

Abbreviations: *S. aureus*, *Staphylococcus aureus*; *E. coli*, *Escherichia coli*; SE, standard error.

bacterial particles. However, when macrophages were incubated with LL-37-coated particles in the presence of M1/70 and heparin, the ability of peptide to boost phagocytosis was diminished by $\sim 70\%$, consistent with the blocking effect of these reagents on cell adhesion. It should be noted that since the combination of heparin and anti-Mac-1 mAb did not produce complete inhibition, other receptors on IC-21 macrophages may contribute to LL-37-mediated phagocytosis.

Since positively charged residues in LL-37 are involved in the interaction with Mac-1 and HSPGs on macrophages, we examined whether other positively charged compounds can

enhance phagocytosis. It is well known that poly-L-lysine supports cell adhesion, and this interaction is completely abolished by heparin. Therefore, we examined the effect of poly-L-lysine on phagocytosis of bacterial particles. No enhancement of phagocytosis by IC-21 macrophages of poly-L-lysine-coated particles was detected (Figure 6A), indicating that the presence of basic residues alone is not sufficient for promoting phagocytosis, while underscoring the requirement for a specific signal provided by Mac-1 recognition motifs present in LL-37.

The effect of LL-37 (5 μ g/mL) on phagocytosis of bacteria by adherent macrophages was also examined. As shown





Figure 7 Augmentation of phagocytosis of LL-37-coated bacteria by adherent macrophages.

Notes: (A) Fluorescently labeled *S. aureus* particles and *E. coli* cells were incubated with LL-37 (5 $\mu\text{g/mL}$) for 20 minutes at 22°C. Soluble peptide was removed by centrifugation and LL-37-coated bacteria were subsequently incubated with adherent IC-21 macrophages or mouse peritoneal macrophages for 60 minutes at 37°C. Data are expressed as mean \pm SE of ratios of bacteria per macrophage. The panels shown in (A) are representative of three or more experiments. $**P \leq 0.01$ compared with untreated control bacteria. (B) A representative experiment showing bright field (a and e), fluorescence (b and f), and merged images (c and g) of IC-21 macrophages exposed to LL-37-coated and uncoated control *S. aureus*. "d" and "h" enlarged images of boxed areas shown in "c" and "g", respectively.

Abbreviations: *S. aureus*, *Staphylococcus aureus*; *E. coli*, *Escherichia coli*; SE, standard error.

in Figure 7A and B, phagocytosis of *E. coli* and *S. aureus* by adherent IC-21 macrophages increased by ~17- and 10-fold, respectively. In addition, LL-37 increased phagocytosis of *E. coli* and *S. aureus* by adherent murine peritoneal macrophages (Figure 7A, shown for *E. coli*). Thus, LL-37 is capable of boosting phagocytosis of bacterial cells by both adherent and nonadherent macrophages.

LL-37 augments phagocytosis of plastic beads via Mac-1

Its high affinity for plastic suggests that LL-37 may promote phagocytosis of foreign bodies. To examine this possibility, we

tested the ability of LL-37 to enhance phagocytosis of latex beads. Preliminary experiments using ^{125}I -labeled LL-37-GY showed that at 10 $\mu\text{g/mL}$, peptide readily bound to the surface of beads ($10.6 \pm 1.3 \text{ fg}/\mu\text{m}^2$). Control and LL-37-treated fluorescent 1 μm beads were incubated with various cells, including IC-21 macrophages, peritoneal mouse macrophages, and human THP-1 cells at a ratio of 10:1 for 30 minutes (a saturation time determined in preliminary experiments), and their phagocytosis was determined (Figure 8A and B). Quantification of phagocytosed beads indicated that LL-37 augmented uptake by ~3.5-, 4.5-, and 6-fold by IC-21, peritoneal macrophages, and THP-1 cells, respectively.




Figure 8 Effect of LL-37 on phagocytosis of latex beads.

Notes: (A) Fluorescent latex beads ($2.5 \times 10^7/\text{mL}$) were preincubated with LL-37 ($10 \mu\text{g}/\text{mL}$) for 20 minutes at 22°C . Soluble peptide was removed from beads by high-speed centrifugation. Peptide-coated beads were incubated with IC-21 cells, mouse peritoneal macrophages, or differentiated THP-1 cells for 30 minutes at 37°C . Nonphagocytosed beads were separated from macrophages by centrifugation. The ratio of beads per macrophage was quantified from three fields of fluorescent images. Data shown are mean \pm SE of triplicate measurements and are representative of three experiments. $*P \leq 0.05$ and $**P \leq 0.01$ compared with untreated beads. (B) Fluorescence of IC-21 macrophages exposed to LL-37-treated beads (a–c) or control untreated beads (e–g). Enlarged images of IC-21 macrophages showing phagocytosed LL-37-treated (d) or control (h) beads. **Abbreviation:** SE, standard error.

Further evidence supporting the role of Mac-1 in LL-37-induced phagocytosis was obtained using macrophages isolated from the peritoneum of wild-type and Mac-1^{-/-} mice. Control and LL-37-coated fluorescent beads were added to adherent wild-type and Mac-1-deficient macrophages for 30 minutes at 37°C , and their phagocytosis was determined. In agreement with previous data that phagocytosis of Mac-1-deficient neutrophils is impaired,^{40,41} phagocytosis of control beads by Mac-1-deficient macrophages was strongly reduced (Figure 9A–C). Pretreatment of beads with LL-37 enhanced their uptake by wild-type macrophages by ~5 times. Phagocytosis of LL-37-coated beads by Mac-1-deficient macrophages was also increased; however, LL-37 failed to enhance phagocytosis to the level observed with wild-type macrophages (Figure 9D). These data suggest that on the

surface of macrophages, Mac-1 is the major receptor responsible for the opsonic function of LL-37.

Discussion

Several mechanisms have been proposed that may account for the ability of the cathelicidin peptide LL-37 to protect the host from infections, including direct pathogen killing and eliciting numerous responses from the immune and other host cells. The immunomodulatory effects of LL-37 have been ascribed to its binding to and/or modulating activity of several unrelated cell surface receptors such as FPRL 1, EGFR, P2X₇, and others.^{12,16–19,42} In this study, we demonstrated that LL-37 is a ligand for the major integrin receptor Mac-1 (CD11b/CD18) on the surface of myeloid cells and found that coating of bacteria with LL-37 augments Mac-1-mediated




Figure 9 Effect of LL-37 on phagocytosis of latex beads by Mac-1-deficient macrophages.

Notes: (A) Resident peritoneal macrophages were obtained from wild-type (WT) and Mac-1^{-/-} mice. LL-37-coated beads were incubated with adherent macrophages for 30 minutes at 37°C. Nonphagocytosed beads were washed, cells treated with trypan blue, and the ratio of beads per macrophage was quantified from three fields of fluorescent images. Data shown are mean \pm SE of triplicate measurements from three experiments. ** $P \leq 0.01$ compared with untreated control beads. (B) Representative confocal image illustrates phagocytosed beads inside a macrophage. The representative fields of WT (C) and Mac-1-deficient (D) macrophages incubated with control and LL-37-coated beads. Bright field (a and d), fluorescence (b and e), and merged (c and f) images of WT and Mac-1-deficient macrophages.

Abbreviation: SE, standard error.

phagocytosis of both gram-negative and gram-positive bacteria. Importantly, LL-37 and its C-terminal K18-37 peptide enhanced phagocytosis at a range of concentrations that are not harmful to mammalian membranes. These observations establish a novel aspect of LL-37 action and suggest a role for this mechanism in the physiologic function of this host defense peptide.

The motivation to investigate the interaction of Mac-1 with LL-37 was our recent finding that LL-37 binds the $\alpha_M I$ -domain, a ligand-binding region of Mac-1, induces a potent migratory response of Mac-1-expressing monocytes and macrophages, and activates Mac-1 on the surface of neutrophils.²⁰ Integrin Mac-1 is a member of the β_2 subfamily of leukocyte integrin adhesion receptors and the major receptor on the surface of neutrophils and monocytes/macrophages. This receptor contributes to leukocyte adhesion to and diapedesis through the inflamed endothelium and controls leukocyte migration to sites of inflammation.^{40,41,43,44} Moreover, ligand engagement by Mac-1 initiates a variety of cellular responses, including phagocytosis, neutrophil degranulation and aggregation, expression of cytokines/chemokines, and other

pro- and anti-inflammatory molecules.^{40,41} Innumerable roles played by Mac-1 in leukocyte biology are thought to arise from its multiligand-binding properties. Indeed, this receptor exhibits broad recognition specificity and is capable of binding an extremely diverse group of protein and nonprotein ligands.²⁵ Screening a large number of the peptide libraries spanning the sequences of Mac-1 protein and peptide ligands for the $\alpha_M I$ -domain binding has allowed us to determine the Mac-1 recognition motif(s).²⁰ In particular, we found that the $\alpha_M I$ -domain binds not to specific amino acid sequence(s) but rather has a preference for the sequence patterns consisting of a core of positively charged residues flanked by hydrophobic residues. Analyses of the LL-37 sequence showed that it contains several potential $\alpha_M I$ -domain recognition cores, and this prediction was experimentally confirmed.²⁰ Furthermore, in this study, we corroborated these data by synthesizing the library of the longer LL-37 derivative, FALL-39 (Figure 1). The interaction of the $\alpha_M I$ -domain with LL-37 was also recently reported by Zhang et al⁴⁵ who used surface plasmon resonance and biolayer interferometry. Interestingly, no interaction of the $\alpha_M I$ -domain with the 13-mer LL-37-derived

peptide FKRIVQRIKDFLR (FK-13) was found.⁴⁵ This result appears to conflict with our data showing that the shorter 9-mer peptide FKRIVQRIK was the most active α_M I-domain-binding peptide in the library (Figure 1). This discrepancy may potentially arise from a high density of peptides within the spots in the library that would favor the interaction with the α_M I-domain or other differences in the experimental format used. However, an alternative explanation, which is supported by our previous studies, may be that FK-13, in contrast to FKRIVQRIK, contains Asp. Indeed, we showed that negatively charged residues were strongly disfavored in the population of the α_M I-domain-binding peptides.²⁰ Further studies of the LL-37-derived sequences and other Mac-1 ligands may help to define the binding specificity of the α_M I-domain.

The role of LL-37 in combating bacterial assault has been shown in several models of infection^{6,45}; however, the precise mechanism by which LL-37 exerts this protective effect has not been determined. Given its ability to directly kill pathogens in vitro, LL-37 was surmised to exert its effect by inserting into and disrupting the bacterial membrane. However, the validity of this mechanism in vivo has been questioned because the direct bactericidal activity was often observed only under low salt conditions and with relatively high concentrations of the peptide.⁶ In the presence of physiological salt concentrations and divalent cations, the antimicrobial activity of LL-37 was significantly reduced and in the presence of tissue culture medium, the peptide had no cytotoxic activity against *S. aureus* or *Salmonella typhimurium* even at concentrations as high as 100 $\mu\text{g/mL}$.^{6,9} The high concentrations of LL-37 that are bactericidal in vitro have been detected in several locations during infection, for example, in bronchoalveolar lavage fluid.⁴⁶ However, such concentrations would seem to not only kill bacteria but also damage neighboring host cells. In this regard, it was previously reported that LL-37 can affect membrane integrity.^{35,36} Our finding that LL-37 at 10 $\mu\text{g/mL}$ induced a small calcein leakage (~ 3 -fold the background level of control untreated cells; data not shown) is in keeping with the harmful effect of high concentrations of the peptide on mammalian cells. While host cells may suffer during the bacterial attack, it is still difficult to imagine an expedient host defense mechanism that turns not only on invaders but also on the host. The defense in which LL-37 spares host cells would seem by far more advantageous. From this perspective, the various immunomodulatory effects of LL-37 observed in standard tissue culture media or whole human blood in vitro^{6,9} may be a more rational explanation for its protective properties,

especially in view of the modest concentrations of LL-37 in vivo. Furthermore, the process in which LL-37 marks the bacterial surface for recognition by macrophages to augment phagocytosis, as described in this study, would primarily target bacteria rather than host cells. It is well established that the differences in the lipid composition between prokaryotic and eukaryotic cell membranes, and in particular, the much higher concentration of negatively charged lipids on the surface of a bacterial cytoplasmic membrane and the presence of anionic lipids on the outer leaflet of gram-negative bacteria allow host defense peptides to preferentially interact with bacterial membranes.^{8,39} This property, however, may be mainly utilized to opsonize rather than kill bacteria. In this respect, it is worth noting that in this study, the concentrations of LL-37 (1–5 $\mu\text{g/mL}$) that have been found to enhance bacterial phagocytosis were significantly lower than the minimal inhibitory concentrations (~ 30 –100 $\mu\text{g/mL}$) required for bacterial killing in physiologically relevant buffers.^{6,47,48}

LL-37 seems to be ideally suited to perform the opsonic function. First, its high positive charge (+6) facilitates the electrostatic interaction with negatively charged phospholipid headgroups of the bacterial surface.⁸ Second, when immobilized on the bacterial surface, LL-37 serves as a ligand for Mac-1, a well-known phagocytic receptor.^{41,49} Third, the relatively small size of LL-37 would create a higher density on the bacterial surface compared with other known opsonins, for example, the complement pathway product iC3b, which is, intriguingly, another Mac-1 ligand.⁵⁰ Fourth, it appears that numerous positively charged residues present in LL-37 are involved in the interaction with macrophage HSPGs, which may strengthen the interaction with the LL-coated bacterial surface. It is worth noting, although, that the positive charge of the polypeptides on its own is not sufficient to induce phagocytosis. This idea is supported by the data that poly-L-lysine was not active in promoting phagocytosis (Figure 6). This is consistent with the hypothesis that the specific interaction of LL-37 with Mac-1 is required to transduce a signal for phagocytosis.

The efficiency of bacterial phagocytosis critically depends upon the opsonization of pathogen as well as the state of macrophage activation. Previous studies reported that several neutrophil-derived granule proteins/peptides opsonize bacteria resulting in enhanced phagocytosis.^{51,52} With regard to LL-37, it was shown that opsonization of oral *Aggregatibacter actinomycetemcomitans* with the peptide resulted in increased phagocytosis by murine macrophages,⁵³ and an uptake of LL-37-coated polystyrene beads by nondifferentiated primary human monocytes was increased compared

with uncoated beads.⁴⁵ On the other hand, bacterial phagocytosis was also shown to be augmented by pretreatment of macrophages with neutrophil secretion products,⁵⁴ including LL-37.²⁷ In two latter studies, pretreatment of macrophages with the neutrophil secretion or with LL-37 was followed by their washing before addition of the bacteria; therefore, direct activation of macrophages was apparently responsible for enhanced phagocytosis. In our studies, we have used a reverse experimental format, that is, pretreatment of bacteria with LL-37 followed by their extensive washing before addition to macrophages. Therefore, opsonization rather than activation was responsible for the increased phagocytosis. It is well established that prior activation of Mac-1 is required for its full phagocytic function.⁵⁵ Therefore, the results of this study in conjunction with our previous findings showing that LL-37 activates Mac-1 on the surface of neutrophil²⁰ suggest that LL-37 may play a dual role, that is, serving as an opsonin and as activator of Mac-1 on phagocytes.

The broad ligand-binding specificity exhibited by Mac-1 and its affinity for peptides/proteins enriched in positively charged, and hydrophobic residues suggest that many other cationic defense proteins/peptides may fulfill the opsonic function through binding of Mac-1. Indeed, screening of several proteins stored in neutrophil granules as well as mammalian cathelicidins and other cationic peptides showed that they bind the α_M I-domain²⁰ (and unpublished data). Consistent with this proposal, we have recently shown that the cationic peptide dynorphin A that was previously shown to enhance phagocytosis⁵⁶ opsonizes bacteria and promotes phagocytosis through Mac-1.⁵⁷ Since negatively charged residues are generally strongly disfavored in the Mac-1 recognition motifs, it is tempting to speculate that the absence of negatively charged residues in some cathelicidin peptides (eg, bovine SMAP-29 and BMAP-27¹) as compared to LL-37 may increase their Mac-1-binding activity. It is also possible that not only LL-37 but also its precursor hCAP-18 or its cathelin domain, which also contains putative Mac-1-binding sites, may increase phagocytosis. Further studies of Mac-1 recognition motifs in cationic host defense peptides may help to determine whether they exhibit phagocytosis-promoting activity.

Considering the rapid emergence of bacterial strains resistant to conventional antibiotics and the exodus of many pharmaceutical companies from the field of antibiotic research and development, there has been an extensive effort to introduce host defense peptides, including LL-37, in clinical practice for the treatment of infectious disease.^{58–60} As the development of therapeutics based on host defense peptides

continues, it is important to gain a better understanding of every aspect of their action. Our finding that LL-37 is an opsonin, which boosts uptake of bacteria by macrophages via a specific engagement of the professional phagocytic receptor Mac-1, provides new insights into the role of this peptide in host defense, but also leaves many questions. Resolving the problems of how the opsonic function of LL-37 is coordinated with other known activities of this peptide and the question whether other cationic proteins/peptides fulfill the phagocytic function via Mac-1 and if so, what is their relative potency, would be of particular interest.

Acknowledgments

The authors thank Yishin Shi, the School of Life Sciences, Arizona State University, for providing *Salmonella* bacterial strains and advice. This article was presented at the Annual Meeting of Experimental Biology, March 28–April 1, 2015, Boston, and published in the abstract form in *FASEB J*, 29:571.15. This work was supported by the NIH grant HL 63199.

Disclosure

The authors report no conflicts of interest in this work.

References

- Zanetti M. The role of cathelicidins in the innate host defenses of mammals. In: Gallo RL, editor. *Antimicrobial Peptides in Human Health and Disease*. Norfolk, UK: Horizon Bioscience; 2005:15–50.
- Sørensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. *Blood*. 2001;97:3951–3959.
- Gundmundsson GH, Agerberth B. Antimicrobial peptides in human blood. In: Gallo RL, editor. *Antimicrobial Peptides in Human Health and Disease*. Norfolk, UK: Horizon Bioscience; 2005:153–174.
- Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. *Infect Immun*. 1999;67(11):6084–6089.
- Cirioni O, Giacometti A, Ghiselli R, et al. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. *Antimicrob Agents Chemother*. 2006;50(5):1672–1679.
- Bowdish DME, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock REW. Impact of LL-37 on anti-infective immunity. *J Leukoc Biol*. 2005;77(4):451–459.
- Zaslouff M. Antimicrobial peptides of multicellular organisms. *Nature*. 2002;415(6870):389–395.
- McPhee JB, Hancock RE. Function and therapeutic potential of host defence peptides. *J Pept Sci*. 2005;11(11):677–687.
- Bowdish DM, Davidson DJ, Hancock REW. A re-evaluation of the role of host defence peptides in mammalian immunity. *Curr Protein Pept Sci*. 2005;6(1):35–51.
- Finlay BB, Hancock RE. Can innate immunity be enhanced to treat microbial infections? *Nat Rev Microbiol*. 2004;2(6):497–504.
- Mookherjee N, Hancock REW. Cationic host defense peptides: innate immune regulatory peptides as a novel approach for treating infections. *Cell Mol Life Sci*. 2007;64(7–8):922–933.
- Yang D, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPR1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, a T cells. *J Exp Med*. 2000;192(7):1069–1074.

13. Scott MG, Davidson DJ, Gold MR, Bowdish DM, Hancock REW. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune response. *J Immunol.* 2002;169(7):3883–3891.
14. Zheng Y, Niyonsaba F, Ushio H, et al. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils. *Br J Dermatol.* 2007;157(6):1124–1131.
15. Nagaoka I, Tamura H, Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. *J Immunol.* 2006;176(5):3044–3052.
16. Tjabringa GS, Aarbiou J, Ninaber DK, et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. *J Immunol.* 2003;171(12):6690–6696.
17. Ellsner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. *J Immunol.* 2004;172(8):4987–4994.
18. Zhang Z, Cherryholmes G, Chang F, Rose DM, Schraufstatter I, Shively JE. Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. *Eur J Immunol.* 2009;39(11):3181–3194.
19. Subramanian H, Gupta K, Guo Q, Price R, Ali H. Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: resistance to receptor phosphorylation, desensitization, and internalization. *J Biol Chem.* 2011;286(52):44739–44749.
20. Podolnikova NP, Podolnikov AV, Haas TA, Lishko VK, Ugarova TP. Ligand recognition specificity of leukocyte integrin $\alpha_M\beta_2$ (Mac-1, CD11b/CD18) and its functional consequences. *Biochemistry.* 2015;54(6):1408–1420.
21. Moon JY, Henzler-Wildman KA, Ramamoorthy A. Expression and purification of a recombinant LL-37 from *Escherichia coli*. *Biochim Biophys Acta.* 2006;1758(9):1351–1358.
22. Yakubenko VP, Solovjov DA, Zhang L, Yee VC, Plow EF, Ugarova TP. Identification of the binding site for fibrinogen recognition peptide γ 383–395 within the α_M I-domain of integrin $\alpha_M\beta_2$. *J Biol Chem.* 2001;276(17):13995–14003.
23. Lishko VK, Podolnikova NP, Yakubenko VP, et al. Multiple binding sites in fibrinogen for integrin $\alpha_M\beta_2$ (Mac-1). *J Biol Chem.* 2004;279(43):44897–44906.
24. Podolnikova NP, Gorkun OV, Loreth RM, Lord ST, Yee VC, Ugarova TP. A cluster of basic amino acid residues in the γ 370–381 sequence of fibrinogen comprises a binding site for platelet integrin $\alpha_{IIb}\beta_3$ (GPIIb/IIIa). *Biochemistry.* 2005;44(51):16920–16930.
25. Yakubenko VP, Lishko VK, Lam SCT, Ugarova TP. A molecular basis for integrin $\alpha_M\beta_2$ ligand binding promiscuity. *J Biol Chem.* 2002;277(50):48635–48642.
26. Lishko VK, Yakubenko VP, Ugarova TP. The interplay between integrins $\alpha_M\beta_2$ and $\alpha_5\beta_1$ during cell migration to fibronectin. *Exp Cell Res.* 2003;283(1):116–126.
27. Wan M, van der Does AM, Tang X, Lindbom L, Agerberth B, Haeggström JZ. Antimicrobial peptide LL-37 promotes bacterial phagocytosis by human macrophages. *J Leukoc Biol.* 2014;95(6):971–981.
28. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. *Eur J Biochem.* 1996;238(2):325–332.
29. Moyle M, Foster DL, McGrath DE, et al. A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18. *J Biol Chem.* 1994;269(13):10008–10015.
30. Chen N, Chen CC, Lau LF. Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin $\alpha_6\beta_1$ and cell surface sulfate proteoglycans. *J Biol Chem.* 2000;275(32):24953–24961.
31. Schober JM, Chen N, Grzeszkiewicz T, et al. Identification of integrin α_{Mb2} as an adhesion receptor on peripheral blood monocytes for Cyr61 and connective tissue growth factor, immediate-early gene products expressed in atherosclerotic lesions. *Blood.* 2002;99(12):4457–4465.
32. Wang G. Structure of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. *J Biol Chem.* 2008;283(47):32637–32643.
33. Ugarova TP, Solovjov DA, Zhang L, et al. Identification of a novel recognition sequence for integrin $\alpha_M\beta_2$ within the gamma-chain of fibrinogen. *J Biol Chem.* 1998;273(35):22519–22527.
34. Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor $\alpha_M\beta_2$ /Mac-1 is critical for host inflammatory response in vivo. *J Clin Invest.* 2004;113(11):1596–1606.
35. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. *J Biol Chem.* 1998;273(6):3718–3724.
36. Zelezetsky I, Pontillo A, Puzzi L, et al. Evolution of the primate cathelicidin. Correlation between structural variations and antimicrobial activity. *J Biol Chem.* 2006;281(29):19861–19871.
37. Niyonsaba F, Iwabuchi K, Someya A, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. *Immunology.* 2002;106(1):20–26.
38. Kocuzalla R, von Degemfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. *J Clin Invest.* 2003;111(11):1665–1672.
39. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. *Biochim Biophys Acta.* 1999;1462(1–2):1–10.
40. Coxon A, Rieu P, Barkalow FJ, et al. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. *Immunity.* 1996;5(6):653–666.
41. Lu H, Smith CW, Perrard J, et al. LFA-1 is sufficient in mediating neutrophil emigration in Mac-1 deficient mice. *J Clin Invest.* 1997;99(6):1340–1350.
42. Kuroda K, Okumura K, Isogai H, Isogai E. The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. *Front Oncol.* 2015;5:144.
43. Ding ZM, Babensee JE, Simon SI, et al. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. *J Immunol.* 1999;163(9):5029–5038.
44. Henderson RB, Lim LHK, Tessier PA, et al. The use of lymphocyte function-associated antigen (LFA)-1-deficient mice to determine the role of LFA-1, Mac-1, and α_4 integrin in the inflammatory response of neutrophils. *J Exp Med.* 2001;194(2):219–226.
45. Zhang X, Bajic G, Andersen GR, Christiansen SH, Vorup-Jensen T. The cationic peptide LL-37 binds Mac-1 (CD11b/CD18) with a low dissociation rate and promotes phagocytosis. *Biochim Biophys Acta.* 2016;1864(5):471–478.
46. Schaller-Bals S, Schulze A, Bals R. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. *Am J Respir Crit Care Med.* 2002;165(7):992–995.
47. Chromek M, Slamová Z, Bergman P, et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. *Nat Med.* 2006;12(6):636–641.
48. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. *Infect Immun.* 2008;76(9):4176–4182.
49. Ross GD, Lambris JD. Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. *J Exp Med.* 1982;155(1):96–110.
50. Ross GD, Cain JA, Lachmann PJ. Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. *J Immunol.* 1985;134(5):3307–3315.
51. Heinzelmann M, Platz A, Flodgaard H, Miller FN. Heparin binding protein (CAP37) is an opsonin for *Staphylococcus aureus* and increases phagocytosis in monocytes. *Inflammation.* 1998;22(5):493–507.
52. Fleischmann J, Selsted ME, Lehrer RI. Opsonic activity of MCP-1 and MCP-2, cationic peptides from rabbit alveolar macrophages. *Diagn Microbiol Infect Dis.* 1985;3(3):233–242.

53. Sol A, Ginesin O, Chaushu S, et al. LL-37 opsonizes and inhibits biofilm formation of *Aggregatibacter actinomycetemcomitans* at subbactericidal concentrations. *Infect Immun*. 2013;81(10):3577–3585.
54. Soehnlein O, Kenne E, Rotzius P, Eriksson EE, Lindbom L. Neutrophil secretion products regulate anti-bacterial activity in monocytes and macrophages. *Clin Exp Immunol*. 2008;151(1):139–145.
55. Ross GD, Vetvicka V. CR3(CD11b,CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. *Clin Exp Immunol*. 1993;92(2):181–184.
56. Ichinose M, Asai M, Sawada M. Enhancement of phagocytosis by dynorphin A in mouse peritoneal macrophages. *J Neuroimmunol*. 1995;60(1–2):37–43.
57. Podolnikova NP, Brothwell JA, Ugarova TP. The opioid peptide dynorphin A induces leukocyte responses via integrin Mac-1 ($\alpha_M\beta_2$, CD11b/CD18). *Mol Pain*. 2015;11:33.
58. Zhang L, Harris SM, Falla TJ. Therapeutic applications of innate immunity peptides. In: Gallo RL, editor. *Antimicrobial Peptides in Human Health and Disease*. Norfolk: Horizon Bioscience; 2005:331–360.
59. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol*. 2006;24(12):1551–1557.
60. Duplantier AJ, van Hoek ML. The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. *Front Immunol*. 2013;4:143.

Supplementary material




Figure S1 Correlation between adhesion of Mac-1-expressing cells to immobilized LL-37-GY and the surface density of plastic-bound LL-37-GY. Various concentrations of ^{125}I -labeled LL-37-GY were immobilized on wells of 96-well microtiter plates under the same conditions used for adhesion assays.

Notes: The plates were washed and bound radioactivity was measured in a γ -counter. Right ordinate shows cpm/well (○) and left ordinate shows fluorescence of cells adherent to wells (●) coated with LL-37-GY.

Research and Reports in Biochemistry

Publish your work in this journal

Research and Reports in Biochemistry is an international, peer-reviewed, open access journal publishing original research, reports, reviews and commentaries on all areas of biochemistry. The manuscript management system is completely online and includes a very quick and fair

peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/research-and-reports-in-biochemistry-journal>

Dovepress